Alphabet‘s (NSDQ:GOOGL) life sciences group, Verily, said today that it won 510(k) clearance from the FDA for its Study Watch for its on-demand electrocardiogram feature. In a blog post published today, the head of Verily’s cardiovascular health innovations unit, Dr. Michael McConnell, wrote that the Study Watch indication covers the recording, storage, transfer and display of […]
Verily eyes new deals with $1B to back them
Alphabet‘s (NSDQ:GOOGL) life sciences group, Verily, said yesterday that it raised $1 billion from a group of investors, including private equity firm Silver Lake and the Ontario Teachers’ Pension Plan. The company plans to use its newly-raised funds to support strategic partnerships and potential acquisitions. In a statement, Verily announced that Alphabet’s chief financial officer, […]
Dexcom inks $250m amended deal with Verily for next-gen diabetes tech
Dexcom (NSDQ:DXCM) said yesterday that it plans to pay $250 million upfront in stock to Verily in an amended collaboration and licensing deal. The two companies are working to develop a second-generation continuous glucose monitoring system. The updated deal also notes that the companies could collaborate on additional products and software. Get the full story at our sister […]
Google’s Verily spikes glucose-sensing lens project with Novartis’ Alcon
Google (NSDQ:GOOG) life sciences company Verily said late last week that it is putting its joint project with Novartis (NYSE:NVS) unit Alcon to develop a glucose-sensing contact lens on hold due to difficulties in obtaining reliable tear glucose readings. The project, which began in 2014, aimed to develop a contact lens that could measure glucose levels for individuals living […]
Google taps ex-Geisinger CEO Feinberg to lead consolidated Google Health biz | Personnel Moves – November 14, 2018
Google (NSDQ:GOOG) has picked up former Geisinger Health CEO David Feinberg to lead its fragmented health divisions under the Google Health moniker, according to a recent CNBC report. The tech giant had been searching for a head for several months, with artificial intelligence head Jeff Dean heavily involved in the process, according to the report. Other […]
ResMed, Google’s Verily ink sleep-apnea-focused joint venture deal
ResMed (NYSE:RMD) and Google (NSDQ:GOOG) life sciences company Verily said today they inked a new joint venture deal aiming to develop software solutions to improve diagnosis, treatment and care for sleep apnea and other breathing related sleep disorders. The new US-based joint venture will use sleep apnea knowledge from San Diego-based ResMed and Verily’s data analytics technologies in its […]
Sensile Medical partners with Verily, Sanofi to develop connected insulin patch pump
Swiss medical device-maker Sensile Medical announced this week that it struck a deal with Verily and Sanofi (NYSE:SNY) to develop and commercialize a connected insulin patch pump. The pre-filled insulin patch pump will be designed primarily for people with Type II diabetes, according to the Olten, Switzerland-based company. Get the full story at our sister site, Drug Delivery Business News.
Here’s how Sanofi separates true innovation from all the hype in digital health
Recognizing that digital technology is here to stay in the business of healthcare, pharmaceutical companies have not shied away from collaborating with the folks in Silicon Valley. Sanofi (NYSE:SNY), for instance, has dove in feet first, striking deals with major tech players like Verily. But weeding out true disruptions from all the noise isn’t easy. “There’s […]
Report: Google’s Verily developing painless blood draw device
Google (NSDQ:GOOG) parent Alphabet‘s (NSDQ:GOOGL) Verily is developing a painless blood collection system using microneedles and magnets, according to a new CNBC report. The system has already been implemented in a working prototype by Verily’s Silicon Valley team, though the company is exploring multiple form factors for the device, according to the report. Commercialization of the moonshot device, which […]
Gilead inks $90m deal with Verily to create “molecular map” of inflammatory disease
Gilead Sciences (NSDQ:GILD) is reportedly slated to pay Alphabet’s Verily Life Sciences $90 million over three years to analyze cells from patients with rheumatoid arthritis, inflammatory bowel disease and lupus-related diseases. By probing immune cells from patients involved in Gilead’s clinical trials, the companies hope to glean a better understanding of the immunological signatures of RA, IBD and […]
Verily, Sanofi and other industry players team up with NIH to advance Parkinson’s therapies
The National Institutes of Health is joining forces with the tech and pharmaceutical industries to speed the development of new drugs for Parkinson’s disease and identify biomarkers for the debilitating condition. Companies participating in the public-private partnership include Celgene (NSDQ:CELG), GlaxoSmithKline (NYSE:GSK), The Michael J. Fox Foundation for Parkinson’s Research, Pfizer (NYSE:PFE), Sanofi (NYSE:SNY) and Verily. Combined the groups plan to commit $12 million to […]
- 1
- 2
- 3
- 4
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube